Nexium Control overview

Nexium Control product range

Ireland’s No 1 pharmacy only 24 hour heartburn protection treatment1

Unlike antacids and alginates that treat the symptoms of heartburn, Nexium Control tackles the cause by targeting acid directly at the source providing long-lasting protection.

For news, updates and access to more resources and webinars please register now to be on our mailing list.

Register now

Nexium Control – Clinically proven protection for frequent heartburn

Benefits of Nexium Control

Long lasting protection

With just one pill a day Nexium Control provides up to 24 hour protection for frequent heartburn sufferers.

Visual of 8 out of 10 people

Clinically proven

8 out of 10 people reported first resolution within the first week of treatment with Nexium Control.

Visual for 4 out of 5 nights heartburn free

Nighttime relief

4 out of 5 nights were heartburn free for patients using Nexium Control.

Nexium Control – Your first line recommendation for frequent heartburn

  • Frequency is key

    Woman speaking to pharmacist

    A key question for heartburn sufferers

    Suffering more than once per week with heartburn is classed as frequent heartburn.

    Regardless of its severity, frequent heartburn makes the oesophagus sensitive to acid such that it does not take a lot to trigger burning pain

    Ask your patients ‘How often do you suffer from heartburn each week?’

    Learn more about how the frequency of heartburn may impact treatment recommendations by clicking here.

  • 24-hour heartburn protection

    Visual of proton pump in stomach

    Break the cycle of short-term heartburn relief with Nexium Control

    Nexium Control is a proton pump inhibitor (PPI) containing 20mg esomeprazole.

    It works by reducing the production of acid in the stomach, providing up to 24 hour protection from heartburn.

    Antacids and alginates only offer short-acting relief from the pain of occasional heartburn until the stomach empties. At this point more acid is produced and the cycle starts again.

    Nexium Control can break the cycle of short-acting relief by reducing the production of stomach acid for up to 24-hours. It treats the cause and symptoms of heartburn, allowing time for the oesophagus to recover from the acid irritation.

      Duration of treatment Mode of action
    Antacids 1-3 hours Neutralises acid content in stomach. Repeated dosing necessary for newly secreted acid.
    Alginates Up to 4 hours Forms a raft on top of stomach contents to prevent escape through sphincter. Repeated dosing necessary for newly secreted acid.
    H2 blockers Up to 12 hours Blocks one of the 3 signals that stimulate acid production. Intermediate duration relief.
    PPI’s e.g. esomeprazole Up to 24 hours Acts on proton pump to reduce acid production. The lack of acid leaking from the stomach gives the oesophagus a ‘holiday’ from acid.

    Find out more about the science behind Nexium control

  • Helping to restore quality of life for sufferers

    Graph of quality of life impacts of frequent heartburn

    Nexium Control helps restore frequent heartburn sufferers’ quality of life

    Frequent heartburn can cause significant disruption to people’s lives, forcing them to avoid certain foods or making it difficult to get a good night’s sleep.

    Research has shown that within just 2 weeks of treatment with esomeprazole, the active ingredient in Nexium Control, the impact on quality of life by heartburn can be significantly improved or normalised.

    Improvements in scores were observed in nearly every quality-of-life parameter measured, including:2

    • Social functioning
    • Vitality
    • Activities affected by emotional or physical health
    • Pain
  • First line treatment for frequent heartburn

    NICE guidelines recommend PPI’s, such as Nexium Control, as first line treatment for frequent heartburn3

Find out more about frequent heartburn

Explore videos, product guides and other resources to support you and your team when recommending Nexium Control for frequent heartburn. Click here

Recommend Nexium Control for your patients with frequent heartburn

Nexium Control tablets pack

Nexium Control 20mg Gastro-Resistant Tablets (Esomeprazole)

Nexium Control 7 tablet pack is an ideal trial pack with one-week supply. Nexium Control 14 tablet pack offers the same protection and offers a 2-week treatment course.

Nexium Control capsules pack shot

Nexium Control 20mg Gastro-Resistant Capsules (Esomeprazole)

Easy-to swallow mini capsules – 53% smaller than tablet* in a portable bottle. Complete 14-day treatment course.

*based on volume

Product Information

Nexium Control 20 mg gastro resistant tablets and hard capsules.Each gastro resistant hard capsule/tablet contains 20 mg esomeprazole (as magnesium trihydrate)Indications: The short term treatment of reflux symptoms (e.g. heartburn and acid regurgitation) in adults.Dosage: The recommended dose is 20 mg esomeprazole (one tablet or capsule) per day. It might be necessary to take the tablets or capsules for 2-3 consecutive days to achieve improvement of symptoms. The duration of treatment is up to 2 weeks. Once complete relief of symptoms has occurred, treatment should be discontinued. If no symptom relief is obtained within 2 weeks of continuous treatment, the patient should be instructed to consult a doctor.Contraindications: Hypersensitivity to the active substance, substituted benzimidazoles or to any of the excipients. Esomeprazole must not be used concomitantly with nelfinavir.Precautions: Jaundice or severe liver disease. Unintentional weight loss, recurrent vomiting, dysphagia, haematemesis or melaena and when gastric ulcer is suspected or present, malignancy should be excluded as treatment with esomeprazole may alleviate symptoms and delay diagnosis. Gastric ulcer or gastrointestinal surgery. Treatment of indigestion or heartburn for 4 or more weeks. Over 55 years old with new or recently changed symptoms. Not suitable for long term use. Treatment with proton pump inhibitors (PPIs) may lead to a slightly increased risk of gastrointestinal infections such as Salmonella and Campylobacter and in hospitalised patients, also possibly Clostridium difficile. Consult doctor prior to have an endoscopy or urea breath test. Co administration with atazanavir is not recommended. Interactions with medicinal products metabolised through CYP2C19 should be considered. The use of esomeprazole with clopidogrel should be discouraged. Patients should not take another PPI or H2 antagonist concomitantly. PPI are associated with very infrequent cases of SCLE. If lesions occur, especially in sun-exposed areas of the skin, and if accompanied by arthralgia, the patient should seek medical help promptly.Pregnancy and lactation: Avoid use of Nexium Control during pregnancy and breast feedingSide effects: Common: headache, abdominal pain, constipation, diarrhoea, flatulence, nausea/ vomiting, fundic gland polyps (benign). Uncommon: peripheral oedema, insomnia, dizziness, paraesthesia, somnolence, vertigo, dry mouth, increased liver enzymes, dermatitis, pruritus, rash urticaria. Rare: leukopenia, thrombocytopenia, hypersensitivity reactions e.g. fever, angioedema and anaphylactic reaction/shock, hyponatraemia, agitation, confusion, depression, taste disturbance, blurred vision, bronchospasm, stomatitis, gastrointestinal candidiasis, hepatitis with or without jaundice, alopecia, photosensitivity, arthralgia, myalgia, malaise, increased sweating. Very rare: agranulocytosis, pancytopenia, aggression, hallucinations, hepatic failure, hepatic encephalopathy in patients with pre-existing liver disease, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis (TEN), muscular weakness, interstitial nephritis, gynaecomastia. Not known: hypomagnesaemia; severe hypomagnesaemia which can correlate with hypocalcaemia; hypomagnesaemia may also result in hypokalaemia, microscopic colitis, subacute cutaneous lupus erythematosus (SCLE).Legal category: Supply through pharmacy only Product licence number: EU/1/13/860/001; EU/1/13/860/002; EU/1/13/860/003; EU/1/13/860/004 and EU/1/13/860/005. MAH: GlaxoSmithKline Consumer Healthcare (Ireland) Limited, 12 Riverwalk, Citywest Business Campus, Dublin 24, Ireland. Full product information is available in the SPC. Additional information is available upon request.Text prepared: July 2021.Contains esomeprazole. Always read the label/leaflet.

Ireland’s No 1 pharmacy only 24 hour heartburn protection treatment1

Icon of stomach

Heartburn

Find out more about frequent heartburn including a profile of a patient who may suffer from the condition.

Find out more

Sign up

Sign up for updates

For news, updates and more, click the link below to sign up and be on our mailing list

Register now

Icon of book

Educational resources

Access educational resources to support your team’s understanding of heartburn and its management.

Find out more